ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC

Shiqi Mao(Tongji University), Shengxiang Ren(Tongji University), Caicun Zhou(Tongji University), Jian Xu(University of California, Los Angeles), Keyi Jia(Tongji University), Qian Liu(Tongji University), Yiwei Liu(Tongji University), Xuefei Li(Harbin Medical University), Bin Chen(Grand Rapids Community College), Chao Zhao(Tongji University), Wanying Wang(Harbin Medical University), Xiaofei Yu(Tongji University), Shuo Yang(Tongji University), Guanghui Gao(Tongji University), Fengying Wu(Shanghai Sixth People's Hospital), Chuchu Shao(Tongji University), Fei Zhou(Shanghai University)
Cancer Immunology Immunotherapy
June 7, 2021
10.1007/s00262-021-02974-9
Cited by 11

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
|Gastric Cancer|2014|615
Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis
|Molecular Carcinogenesis|2010|558
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467